Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery

Volumn 133, Issue 6, 2007, Pages

  Downey, Robert J ^a   Akhurst, Timothy ^a   Gonen, Mithat ^a   Park, Bernard ^a   Rusch, Valerie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

EID: 34249037197     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2007.01.041     Document Type: Article

References (18)

1. Duhaylongsod F.G., Lowe V.J., Patz Jr. E.F., Vaugh Al., Coleman R.E., and Wolfe W.G. Lung tumor growth correlates with glucose metabolism measured by fluorine-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60 (1995) 1348-1352
2. Vesselle H., Schmidt R.A., Pugsley J.M., Li M., Kohlmyer S.G., Vallires E., et al. Lung cancer proliferation correlates with [F-18] fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6 (2000) 3837-3844
3. Downey R.J., Akhurst T., Gonen M., Vincent A., Bains M.S., Larson S., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22 (2004) 3255-3260
4. Ahuja V., Coleman R.E., Herndon J., and Patz E.F. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83 (1998) 918-924
5. Cerfolio R.J., Bryant A.S., Ohja B., and Bartolucci A.A. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 130 (2005) 151-159
6. Dhital K., Saunders C.A.B., Seed P.T., O'Doherty M.J., and Dussek J. 18F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 18 (2000) 425-428
7. Higashi K., Ueda Y., Arisaka Y., Sakuma T., Nambu Y., Oguchi M., et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resection non-small cell lung cancer. J Nucl Med 43 (2002) 39-45
8. Jeong H.-J., Min J.-J., Park J.M., Chung J.-K., Kim B.T., Jeong J.M., et al. Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23 (2002) 865-870
9. Kieninger A.N., Welsh R., Bendick P.J., Zelenock G., and Chmielewski G.W. Positron-emission tomography as a prognostic tool for early-stage lung cancer. Am J Surg 191 (2006) 433-436
10. Port J.L., Andrade R.S., Levin M.A., Korst R.J., Lee P.C., Becker D.E., et al. Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less. J Thorac Cardiovasc Surg 130 (2005) 1611-1615
11. Sasaki R., Komaki R., Macapinlac H., Erasmus J., Allen P., Forster K., et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23 (2005) 1136-1143
12. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., De Leyn P.R., Verbeken E.K., Deneffe G.J., et al. Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. J Clin Oncol 17 (1999) 3201-3206
13. Sugawara Y., Quint L.E., Iannettoni M.D., Orringer M.B., Russo J.E., Recker B.E., et al. Does the FDG uptake of primary non-small cell lung cancer predict prognosis?: A work in progress. Clin Positron Imaging 2 (1999) 111-118
14. Vesselle H., Turcotte E., Wiens L., Schmidt R., Takasagui J.E., Lalani T., et al. Relationship between non-small cell lung cancer fluorodeoxyglucose uptake at positron emission tomography and surgical stage with relevance to patient prognosis. Clin Cancer Res 10 (2004) 4709-4716
15. Borst G.R., Belderbos J.S.A., Boellaard R., Comans E.F.I., De Jaeger K., Lammertsma A.A., et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 41 (2005) 1533-1541
16. Pillot G., Siegel B.A., and Govindan R. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer. A review. J Thorac Oncol 1 (2006) 152-159
17. Cerfolio R.J., Bryant A.S., Ojha B., and Eloubeidi M. Improving the inaccuracies of clinical staging of patients with NSLCC: a prospective trial. Ann Thorac Surg 80 (2005) 1207-1213
18. Roberts J.R., Blum M.G., Arildsen R., Drinkwater Jr. D.C., Christian K.R., Powers T.A., et al. Prospective comparison of radiologic, thoracoscopic, and pathologic staging in patients with early non-small cell lung cancer. Ann Thorac Surg 68 (1999) 1154-1158